Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

NCT04146298 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT04146298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04146298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Lead sponsor
Changhai Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 21, 2021
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, pancreatic neoplasms